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Abstract. One of the key research agenda of the field of aging is investigation of presymptomatic Alzheimer’s disease
(AD). Furthermore, abnormalities in brain glucose metabolism (as measured by FDG-PET) have been reported among
cognitively normal elderly persons. However, little is known about the association of FDG-PET abnormalities with neu-
ropsychiatric symptoms (NPS) in a population-based setting. Thus, we conducted a cross-sectional study derived from the
ongoing population-based Mayo Clinic Study of Aging in order to examine the association between brain glucose metabolism
and NPS among cognitively normal (CN) persons aged > 70 years. Participants underwent FDG-PET and completed the
Neuropsychiatric Inventory Questionnaire (NPI-Q), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI).
Cognitive classification was made by an expert consensus panel. We conducted multivariable logistic regression analyses to
compute odds ratios (OR) and 95% confidence intervals after adjusting for age, sex, and education. For continuous variables,
we used linear regression and Spearman rank-order correlations. Of 668 CN participants (median 78.1 years, 55.4% males),
205 had an abnormal FDG-PET (i.e., standardized uptake value ratio < 1.32 in AD-related regions). Abnormal FDG-PET
was associated with depression as measured by NPI-Q (OR = 2.12; 1.23–3.64); the point estimate was further elevated for
APOE ε4 carriers (OR = 2.59; 1.00–6.69), though marginally significant. Additionally, we observed a significant association
between abnormal FDG-PET and depressive and anxiety symptoms when treated as continuous measures. These findings
indicate that NPS, even in community-based samples, can be an important additional tool to the biomarker-based investigation
of presymptomatic AD.
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INTRODUCTION
Abnormal brain changes precede cognitive out-
comes by several years or decades [1–3]. Accord-
ingly, the field of cognitive research is increasingly
emphasizing the importance of investigating the
presymptomatic phase of Alzheimer’s disease (AD)
using biomarkers such as fluorodeoxyglucose-
positron emission tomography (FDG-PET) [4, 5].
Furthermore, given the extensive and reciprocal neu-
ronal connections between structures that mediate
emotion and the epicenter of cognition [6], it is
critical to investigate the associations of neuropsy-
chiatric symptoms (NPS) with FDG-PET, a marker
of synaptic dysfunction, among cognitively normal
participants [7, 8].
We addressed this knowledge gap by utilizing the
research setting of the ongoing, population-based
Mayo Clinic Study of Aging. We conducted a cross-
sectional study to examine the association between
brain glucose metabolism as measured by FDG-PET
and NPS among cognitively normal participants.
METHODS
Setting and study design
This cross-sectional study was conducted in the
setting of the Mayo Clinic Study of Aging (MCSA).
Details of the study procedures have been reported
elsewhere [9]. Briefly, the MCSA is an ongoing
population-based study of normal cognitive aging and
mild cognitive impairment (MCI) in Olmsted County,
Minnesota. The sample for the current study con-
sisted of 668 cognitively normal (CN) individuals
aged 70 years and above on whom FDG-PET, APOE
genotyping, and NPS data were available.
The study was approved by the institutional review
boards of Mayo Clinic and Olmsted Medical Center,
and informed consent for participation was obtained
from every participant.
Cognitive evaluation
Participants underwent three face-to-face eval-
uations: 1) risk factor ascertainment (including
Neuropsychiatric Inventory Questionnaire (NPI-Q
[10]) and baseline evaluation (including Clinical
Dementia Rating Scale [11]) performed by a nurse
or study coordinator; 2) neurological evaluation
including a neurological interview, Short Test of
Mental Status [12], and neurological examination
performed by behavioral neurologists; 3) neuropsy-
chological evaluation of four cognitive domains –
memory (delayed recall trials from the Auditory
Verbal Learning Test [13] and the Wechsler Mem-
ory Scale-Revised [14], Logical Memory and Visual
Reproduction subtests); language (Boston Naming
Test [15] and category fluency); visuospatial (Wech-
sler Adult Intelligence Scale-Revised [16], Picture
Completion and Block Design subtests); and exec-
utive function (Trail Making Test Part B [17] and
the Wechsler Adult Intelligence Scale-Revised, Digit
Symbol subtest).
All tests were administered by psychometrists who
were supervised by neuropsychologists. An expert
consensus panel of physicians, neuropsychologists,
and nurses or study coordinators reviewed the data
and made a diagnosis of normal cognition, MCI, or
dementia based on published criteria.
Measurement of neuropsychiatric symptoms
(depression, anxiety, agitation, apathy)
NPS were measured using the NPI-Q. The NPI-Q
is a shorter version of the Neuropsychiatric Inventory,
a validated clinical instrument [10]. We consid-
ered the NPI-Q an appropriate screening instrument
because it assesses a broad variety of NPS and was
also selected by the Uniform Data Set Initiative of the
National Institute on Aging [18]. It was administered
as a structured interview to an informant, usually
the spouse. The NPI-Q is designed to obtain infor-
mation on 12 emotional behaviors (i.e., agitation,
delusion, hallucination, depression, anxiety, eupho-
ria, apathy, disinhibition, irritability, aberrant motor
behavior, sleep, and eating/appetite).
As reported previously [19, 20], delusions, hal-
lucinations, and euphoria are extremely rare events
thus no meaningful analyses could be made regarding
these symptoms.
Measurement of anxiety and depression using
BAI and BDI
Anxiety symptoms were measured using the Beck
Anxiety Inventory (BAI) [21]. The BAI is a vali-
dated, self-administered questionnaire consisting of
21 items that are assessed over the last week. The
severity of each symptom is rated ranging from 0 to
3 with a total score ranging from 0 to 63.
Depressive symptoms were measured using
the validated, self-administered Beck Depression
J. Krell-Roesch et al. / FDG-PET and Neuropsychiatric Symptoms among Cognitively Normal Elderly Persons 1611
Inventory-II (BDI-II) which is a sensitive instrument
in elderly individuals [22]. Similar to the BAI, the
BDI-II is an ordinal measure that consists of 21 items
that are assessed over the last two weeks and are rated
in severity ranging from 0 to 3. Thus, the total scores
can range from 0 to 63.
FDG-PET measurement
366-399 MBq of 18FDG was injected intra-
venously to all study participants followed by an
uptake period of 30 min. During this time, the par-
ticipants were left undisturbed in a darkened room
and instructed to rest quietly without activity with
their eyes open. Afterwards participants were imaged
with their eyes open for an 8-min image acquisition
consisting of four 2-min dynamic frames. Also, a CT
image was obtained for attenuation correction.
Quantitative image analysis for FDG PET was per-
formed using our in-house fully automated image
processing pipeline [23, 24]. Statistics on image voxel
values were extracted from automatically labeled cor-
tical regions of interest (ROIs) using an atlas [25]
modified in-house. There were 19 regions of interest
after combining the left and right regions from the
atlas. The meta-region of interest consisted of bilat-
eral angular gyrus, posterior cingulate/precuneus,
and inferior temporal cortical regions from both
hemispheres and was identified as AD signature ROI
elsewhere [26–28]. The ratio of this AD signature
ROI and the pons as well as the cerebellar vermis
is referred to as the standardized uptake value ratio
(SUVR). These two regions of references were cho-
sen because they have preserved glucose metabolism
in AD [29]. We defined an abnormal FDG-PET ratio
as SUVR less than 1.32 [30, 31].
APOE genotyping
Blood was drawn from the study participants after
obtaining informed consent. Then, APOE ε4 geno-
types were determined from DNA using a polymerase
chain reaction amplification [32]. The laboratory
technicians were blinded to other study variables.
Statistical analysis
Categorical analysis
We conducted multivariable logistic regression
analyses to examine the association between brain
metabolism as measured by FDG-PET and the odds
of having NPS (defined as presence or absence of
anxiety, depression, apathy, agitation as measured by
NPI-Q). We computed odds ratios (OR) and 95%
confidence intervals (95% CI) and adjusted for age
(continuous variable), sex, and education (continu-
ous variable). OR (95% CI) were used to compare
the odds of having NPS between two groups: 205
participants with an abnormal FDG-PET versus 463
participants with a normal FDG-PET. We also con-
ducted a stratified analysis by APOE ε4 carrier
status.
Continuous analysis
We calculated linear regression analyses and
Spearman rank-order correlations between FDG-
PET ratio (as continuous variable) and Beck Anxiety
Inventory as well as Beck Depression Inventory
(as continuous variables) and adjusted for age,
sex, and education. Statistical testing was done at
the conventional 2-tailed alpha level of p < 0.05.
Statistical analyses were performed using SAS Sys-
tem, version 9.3 software (SAS Institute, Cary,
NC).
RESULTS
Baseline demographic characteristics
The demographic characteristics of the sample are
summarized in Table 1. Two hundred five participants
had an abnormal FDG-PET and 463 participants had
a normal FDG-PET. The two groups differed signif-
icantly in age and sex. However, the comparison of
NPS between the two groups was done after adjusting
for age, sex, and education.
Categorical analysis of NPS based on NPI-Q
Depression was the most common symptom,
affecting 31 (15.2%) of participants with an abnor-
mal FDG-PET and 33 (7.3%) of participants with
a normal FDG-PET. Participants with an abnor-
mal FDG-PET were more than twice as likely to
have depression as compared to participants with
normal FDG-PET (OR = 2.12; 1.23, 3.64). Addition-
ally, the point estimates were elevated for anxiety
(OR = 1.61; 0.76-3.42), and agitation (OR = 1.21,
0.38–3.79) but none reached statistical significance.
Additional adjustment for history of depression did
not alter the results. Details of the findings are dis-
played in Table 2.
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Table 1
Demographic characteristics of study participants
Variable Abnormal FDG-PET Normal FDG-PET p
(N = 205) (N = 463) p
Male Gender, n (%) 125 (61.0) 238 (51.4) 0.023
Age at visit date (years)a 80.3 (76.7, 84.1) 77.2 (73.8, 82.0) <0.001
70–79, n (%) 96 (46.8) 309 (66.7)
80–95, n (%) 109 (53.2) 154 (33.3)
Education (years)a 14.0 (12.0, 16.0) 14.0 (12.0, 16.0) 0.673
>12 years, n (%) 131 (63.9%) 302 (65.2%) 0.792
APOE ε4+, n (%)b 57 (27.8) 112 (24.2) 0.327
aMedian (interquartile range), b4 patients missing APOE ε4 status.
Table 2
NPS and FDG-PET
NPS Abnormal FDG-PET Normal FDG-PET OR (95% CI)
(N = 204) (N = 454)
n (%) n (%)
Agitation 5 (2.5) 9 (2.0) 1.21 (0.38–3.79)
Depression 31 (15.2) 33 (7.3) 2.12 (1.23–3.64)*
Anxiety 13 (6.4) 19 (4.2) 1.61 (0.76–3.42)
Apathy/Indifference 9 (4.4) 20 (4.4) 0.86 (0.37–1.97)
∗p≤ 0.05. Note: Neuropsychiatric data were missing for 1 participant with an abnormal FDG-PET and 9 participants
with a normal FDG-PET. In this analysis, we only included participants in which NPS (agitation, depression, anxiety,
and apathy as measured by NPI-Q) were present.
Measurement of depressive and anxiety
symptoms on a continuous scale
Even though BDI and BAI are ordinal scales,
we treated the data as continuous. FDG-PET ratios
were significantly associated with both, BDI score
(–0.0036, SE = 0.0012, p = 0.004) and BAI score
(–0.0033, SE = 0.0015, p = 0.030) in a linear regres-
sion analysis that was adjusted for age, sex, and
education. Similarly, when we calculated Spearman
correlations, the correlation between FDG-PET ratio
and BDI score (r = –0.10, p = 0.007) as well as BAI
score (r = –0.11, p = 0.007) was significant.
Categorical analysis of NPS: Stratiﬁed
by APOE ε4
We conducted a stratified analysis by APOE ε4
genotype (any versus none) among participants with
an abnormal FDG-PET for additional understanding
of the data. As expected, the point estimates of having
NPS were consistently higher for APOE ε4 carri-
ers than APOE ε4 non-carriers with the exception
of anxiety. Participants who were APOE ε4 carriers
and had an abnormal FDG-PET, had double the odds
of having depression, even though the association
was marginally significant (OR = 2.59; 1.00–6.69;
p = 0.050). The point estimate was also elevated
though not significant in APOE ε4 non-carriers who
had an abnormal FDG-PET (OR = 1.86; 0.97–3.57;
p = 0.063).
Secondary analysis: Speciﬁc regions of interest
We ran additional multiple regression analyses to
investigate the association between depression, anx-
iety and specific regions of interest. We adjusted the
models for age, sex, education, depression medica-
tion, medical comorbidities, and global cognition.
We did not observe any significant associations and
the point estimates were very small as expected.
However, we observed a tendency of an inverse rela-
tionship between the point estimates and the regional
glucose uptake, i.e., the higher the depressive or anx-
iety symptoms, the lower the glucose uptake. Please
refer to Table 3.
DISCUSSION
Here we report a population-based cross-sectional
study that investigated the association between brain
metabolism as measured by FDG-PET and neuropsy-
chiatric symptoms among cognitively normal elderly
persons after adjusting for age, sex, and education.
The study was driven by our desire to under-
stand whether brain glucose metabolism as measured
by FDG-PET was associated with neuropsychiatric
symptoms in cognitively normal persons and thereby
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Table 3
Depression, anxiety, and regions of interest
ROI BDI (N = 655) p BAI (N = 655) p
Anterior Cingulate –0.0014 (–0.0033, 0.0005) 0.14 –0.0015 (–0.0038, 0.0008) 0.20
Prefrontal –0.0015 (–0.0040, 0.0011) 0.26 –0.0013 (–0.0044, 0.0018) 0.41
Temporal –0.0006 (–0.0026, 0.0013) 0.52 –0.0000 (–0.0023, 0.0023) 0.99
Caudate –0.0015 (–0.0036, 0.006) 0.15 –0.0019 (–0.0044, 0.0006) 0.13
Insula –0.0011 (–0.0028, 0.0006) 0.21 –0.0009 (–0.0029, 0.0012) 0.40
Medial Temporal –0.0001 (–0.0013, 0.0011) 0.86 –0.0000 (–0.0014, 0.0014) 1.00
Parietal –0.0012 (–0.0041, 0.0017) 0.42 –0.0008 (–0.0042, 0.0027) 0.67
Thalamus –0.0004 (–0.0024, 0.0015) 0.66 –0.0009 (–0.0033, 0.0014) 0.44
increase our understanding of the preclinical phase
of AD [4].
In the categorical analysis based on data from the
NPI-Q, we observed that depression was associated
with an abnormal FDG-PET among cognitively nor-
mal elderly persons. Participants with an abnormal
FDG-PET were twice as likely to have depression
as compared to individuals with a normal FDG-PET.
Additionally, we also observed that depressive and
anxiety symptoms were associated with abnormal
FDG-PET when treated as continuous variables as
derived from BDI and BAI. To investigate whether
the findings could be biased by concomitant use of
medications, we compared medication intake (e.g.,
SSRI/SNRIs) between participants with a normal ver-
sus abnormal FDG-PET. We did not observe any
significant differences between the two groups for
either class of medications.
In a secondary analysis, we examined the associ-
ation between regions of interest that are reported in
the literature to be associated with major depressive
disorder [33] and anxiety disorders [34]. We sought to
investigate if these ROI were also associated with sub-
syndromal depressive and anxiety symptoms. Indeed,
we observed a small inverse yet non-significant rela-
tionship between depressive and anxiety symptoms
and specific regions of interest. This was expected
given that our participants are community-dwelling,
cognitively normal elderly individuals. Therefore, on
average, they are less likely to have clinically signif-
icant depressive and anxiety symptoms. In previous
studies, hippocampal atrophy was reported in severe
recurrent depression in clinical samples [35]. How-
ever, we did not observe this in our sample.
To our knowledge, only one study investigated the
association between FDG-PET and depressive symp-
toms in normal aging [36]. Investigators from Mas-
sachusetts General Hospital analyzed FDG-PET data
on a volunteer sample of 248 community-dwelling
older adults. They measured depression using the
Geriatric Depression Scale (GDS). Consistent with
our finding they reported that depression was associ-
ated with FDG-PET hypometabolism, even though
their effect size is smaller. However, they also
reported a significant association between FDG-
PET hypometabolism and apathy, which we did not
observe in our data. The differences in our find-
ings could be attributable to various factors. These
factors could include the difference in the measure-
ment of depressive symptoms as we used NPI-Q and
BDI and they used GDS. Another possible explana-
tion for the differences could be the way in which
study participants were recruited. The investigators
from Boston used a volunteer sample of community-
dwelling older adults whereas we had a randomized,
population-based sample of elderly individuals.
In the past, few studies have investigated the asso-
ciation between NPS and FDG-PET in MCI and
clinical AD samples [37–42]. However, those studies
were not directly relevant to our study because our
study participants were cognitively normal persons.
As APOE ε4 genotype is a well-known genetic risk
factor for AD, we also examined its role in influenc-
ing the association between NPS and brain glucose
metabolism by conducting a stratified analysis. We
observed that APOE ε4 carriers who had an abnor-
mal FDG-PET were more than twice as likely to
have depression as compared to non-carriers, even
though this association was marginally significant.
Previous studies found an association between APOE
ε4 genotype and reduced brain glucose metabolism
[43, 44], but there is essentially no study available on
the association between NPS and FDG-PET as strati-
fied by APOE ε4 genotype among cognitively normal
persons.
Our findings should be interpreted in the context
of the strengths and limitations of this study. The
strength of our study pertains to the large, population-
based sample size. In addition, all study partici-
pants underwent numerous face-to-face evaluations
including FDG-PET scans. They were classified
as cognitively normal or having MCI or dementia
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based on a consensus panel at a center with a well-
established track record in the field of aging and
MCI. Furthermore, our study could be one of the few
that investigated the association between depression,
anxiety and specific AD-related brain regions among
cognitively normal elderly persons.
Our study also has limitations. As in any cross-
sectional study, it is not possible to determine the
direction of causality between the exposure of interest
(i.e., neuropsychiatric symptoms) and the outcome of
interest (i.e., FDG-PET). Another limitation pertains
to the use of the NPI-Q, which is an informant-
based assessment and may therefore be prone to recall
bias. However, it must be noted that the NPI-Q is a
validated and common tool to assess neuropsychi-
atric symptoms that has been used in a variety of
other large-scale studies in the field. Also, one of
the limitations of the study was that we were not
able to examine the association of neuropsychiatric
symptoms with regions of interest stratified by hemi-
sphere (right versus left); such an approach would
have required twice as much power. A future, much
larger sample that specifically seeks to test an a priori
hypothesis of laterality can address this question.
The current key research agenda of the field of
aging is a biomarker-based investigation of presymp-
tomatic AD. This may be one of the first studies
to address this research question in the context of
emotional behaviour. We observed that depression
and anxiety are associated with an abnormal FDG-
PET. Our findings suggest that interventions that
target biomarkers of presymptomatic AD may need
to account for depressive and anxiety symptoms. Our
study finding may also be relevant to the construct
of mild behavioral impairment (MBI). Based on our
findings, we hypothesize that MBI subjects with an
abnormal FDG-PET may constitute a subset of MBI
that may need to be followed to determine if they are
at higher risk for clinical AD. However, our finding
should be considered as preliminary until confirmed
by a cohort study.
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